<DOC>
	<DOC>NCT02406261</DOC>
	<brief_summary>The purpose of this study is to study the effect of AZD3293 on how the body absorbs and processes 3 other medications, midazolam, simvastatin and donepezil and how these 3 medications affect AZD3293 when they are taken together. This study is in 2 groups, group A is approximately 44 days long and group B about 70 days only. The screening visit is required within 30 days prior to the start on the study</brief_summary>
	<brief_title>A Drug-drug Interaction Study of AZD3293 (LY3314814) in Healthy Participants</brief_title>
	<detailed_description>Astra Zeneca (AZ) registered this trial as sponsor. In July, 2015, sponsorship changed to Eli Lilly and Company (Lilly). In August, 2015, AZ transferred this trial to Lilly's ClinicalTrials.gov account and Lilly updated the record. This trial is not an applicable trial under the Food and Drug Administration Amendments Act of 2007 (FDAAA).</detailed_description>
	<mesh_term>Donepezil</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>Overtly healthy and either sterile or, male and prepared to use an approved method of contraception Have a body mass index (BMI) at screening of 19.0 to 32.0 kilogram per square meter (kg/m^2) History of any clinically significant disease or disorder which, in the opinion of the Investigator, may put the subject at risk because of participation in the study, may influence the results, or may limit the subject's ability to participate in the study History or presence of gastrointestinal, hepatic or renal disease or any other condition known to interfere with absorption, distribution, metabolism or excretion of drugs History of previous or ongoing psychiatric disease/condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>